Last updated on December 2018

Human Mesenchymal Stem Cells (LMSCs) on Vaccine-Specific Antibody- Response in Subjects With Aging Frailty


Brief description of study

This is a phase I/II, randomized, blinded and placebo-controlled study to test the safety and efficacy of LMCSs for improving vaccine immune response.

Detailed Study Description

A pilot phase will consist of a 3 subject safety run-in, followed by 20 subject randomized phase to evaluate influenza vaccine response at 1 week and 4 weeks post infusion of LMSCs. This will be followed by a double-blinded, randomized, placebo-controlled phase.

Clinical Study Identifier: NCT02982915

Contact Investigators or Research Sites near you

Start Over

Dushyantha T. Jayaweera, MD

University of Miami
Miami, FL United States
  Connect »

Antonio Blanco, MD

Vista Health Research
Miami, FL United States
  Connect »

Jeffrey Rosen, MD

Clinical Research of South Florida
Coral Gables, FL United States
  Connect »

Pedro P Ylisastigui, MD

Clinical Physiology Associates
Fort Myers, FL United States
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.